Bempegaldesleukin

IsoPlexis' Blood-Based Biomarker Predicts Response and Progression-Free Survival to a Novel IL-2 Agonist and Checkpoint Inhibitor Doublet Therapy in a Phase 2 Study of Metastatic Melanoma Patients

Retrieved on: 
Thursday, November 12, 2020
Cancer treatments, Clinical medicine, Medicine, Bristol-Myers Squibb, Cancer immunotherapy, Monoclonal antibodies, Antineoplastic drugs, Breakthrough therapy, Nivolumab, Bempegaldesleukin, Melanoma, Immunotherapy

The presented data from the clinical trial examines T cell response to Nivolumab (Nivo) immunotherapy in combination with Nektar's bempegaldeskleukin (NKTR-214, BEMPEG) IL-2 pathway agonist.

Key Points: 
  • The presented data from the clinical trial examines T cell response to Nivolumab (Nivo) immunotherapy in combination with Nektar's bempegaldeskleukin (NKTR-214, BEMPEG) IL-2 pathway agonist.
  • IsoPlexis' technology identified a non-invasive, blood-based biomarker predicted response to the doublet.
  • IsoPlexis' functional immune landscaping has been used to profile the effects of BEMPEG in both monotherapy and combination immunotherapies in a clinical setting.
  • The presentation titled "Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study," was presented on November 11th.

ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology

Retrieved on: 
Monday, March 30, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Immune system, CD8, Cytotoxic T cell, AstraZeneca, Immunotherapy, T cell, Bempegaldesleukin

Commenting on the news,Ian Wilson, Chief Executive Officer of ImaginAb said:"We are very pleased that AstraZeneca is expanding our relationship.

Key Points: 
  • Commenting on the news,Ian Wilson, Chief Executive Officer of ImaginAb said:"We are very pleased that AstraZeneca is expanding our relationship.
  • Under the new agreement, ImaginAb will provide AstraZeneca with clinical doses of ImaginAb's CD8 ImmunoPET minibody, as well as technical support, to AstraZeneca clinical trials involving novel immunotherapies.
  • ImaginAb's CD8 ImmunoPET technology is the clinically most advanced CD8 PET tracer.
  • CD8 ImmunoPET minibody [89Zr-Df-IAB22M2C] binds CD8 receptor on human T cells and is used for non-invasive PET imaging of CD8 T cells in patients.

ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology

Retrieved on: 
Monday, March 30, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Immune system, CD8, Cytotoxic T cell, AstraZeneca, Immunotherapy, T cell, Bempegaldesleukin

Commenting on the news,Ian Wilson, Chief Executive Officer of ImaginAb said:"We are very pleased that AstraZeneca is expanding our relationship.

Key Points: 
  • Commenting on the news,Ian Wilson, Chief Executive Officer of ImaginAb said:"We are very pleased that AstraZeneca is expanding our relationship.
  • Under the new agreement, ImaginAb will provide AstraZeneca with clinical doses of ImaginAb's CD8 ImmunoPET minibody, as well as technical support, to AstraZeneca clinical trials involving novel immunotherapies.
  • ImaginAb's CD8 ImmunoPET technology is the clinically most advanced CD8 PET tracer.
  • CD8 ImmunoPET minibody [89Zr-Df-IAB22M2C] binds CD8 receptor on human T cells and is used for non-invasive PET imaging of CD8 T cells in patients.

Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study

Retrieved on: 
Wednesday, March 25, 2020
Medical specialties, Medicine, Branches of biology, Immune system, Immunology, T cells, Regulatory T cell, Tumor, Lymphocytes, Natural killer cell, Tumor microenvironment, Bempegaldesleukin

The presentation (details below) will highlight data from the long-acting variant MDNA19, engineered to have enhanced binding to CD122 without binding to CD25.

Key Points: 
  • The presentation (details below) will highlight data from the long-acting variant MDNA19, engineered to have enhanced binding to CD122 without binding to CD25.
  • This allows MDNA19 to specifically activate nave CD8 T cells and natural killer (NK) cells with minimal stimulation of T regulatory cells (Tregs), thereby circumventing toxicity and demonstrating potential for best-in-class features.
  • Furthermore, MDNA19 treatment of B16F10 tumors favored activation of CD8 T cells over Tregs in the tumor microenvironment driving a strong therapeutic effect.
  • More than 25 years pharmaceutical development experience, mostly at Novartis, in both the early and late development arena.

Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders

Retrieved on: 
Friday, January 10, 2020
Legal, Professional services, Biotechnology, PEGylation, Pharmacokinetics, RTT, Nektar, Cancer, Treatment of cancer, Life sciences, Nektar Therapeutics, Bempegaldesleukin

Nektar develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.

Key Points: 
  • Nektar develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.
  • The company's lead clinical-stage drug is NKTR-214, a modified version of cytokine IL-2
    If you suffered a loss as a result of Nektar's misconduct, click here .
  • According to the complaint, Nektar touted to investors that NKTR-214 was a promising new universal cancer treatment drug.
  • In addition, the report alleged that pegylation impaired the efficacy of NKTR-214, rendering it "completely useless for treating cancer."

Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

Retrieved on: 
Friday, January 10, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Clinical medicine, Monoclonal antibodies, Life sciences, Antineoplastic drugs, Breakthrough therapy, Bempegaldesleukin, Bristol-Myers Squibb, Nivolumab, Nektar Therapeutics, Squib, Bristol-Myers Squibb, the Bristol-Myers Squibb and Ono Pharmaceutical Collaboration, Nektar Therapeutics

Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials.

Key Points: 
  • Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials.
  • The costs for these studies will be shared based upon the cost-sharing outlined in the terms of the original collaboration agreement.
  • Bristol-Myers Squibb and Nektar view bempeg as an important asset and IL-2 as an important target, said Fouad Namouni, M.D., head of oncology development, Bristol-Myers Squibb.
  • Withhold OPDIVO monotherapy for Grade 2 or 3 and permanently discontinue for Grade 4 or recurrent colitis upon re-initiation of OPDIVO.